Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection

• Status: NOT_YET_RECRUITING
• Trial end date: 2028-09-01

Summary

This multicenter, randomized, double-blind, placebo-controlled trial evaluates the efficacy and safety of ketorolac in 360 patients with Stanford Type A aortic dissection, conducted between 2025 and 2027. Participants will receive either ketorolac (60 mg intramuscularly \[IM\] preoperatively and 30 mg twice daily \[BID\] for two days postoperatively) or placebo in addition to standard care. Study outcomes include composite clinical endpoints, postoperative complications, and adverse events, which will be assessed through clinical evaluations, laboratory testing, and imaging studies at predefined intervals up to 90 days. The objective of this trial is to determine whether perioperative administration of ketorolac improves clinical outcomes in this patient population.

• Phase: PHASE3

Details

• Lead Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
• Collaborators: First Affiliated Hospital of Harbin Medical University; Guangdong Provincial People's Hospital; Huai'an First People's Hospital; Shandong Provincial Hospital; THE FIRST AFFILIATED HOSPITAL OF SHIHEZI UNIVERSITY; The Second Affiliated Hospital of Harbin Medical University; Xinhua Hospital of Ili Kazak Autonomous Prefecture
• Treatments: Ketorolac; Sodium Chloride